[Code of Federal Regulations]
[Title 40, Volume 14]
[Revised as of July 1, 2003]
From the U.S. Government Printing Office via GPO Access
[CITE: 40CFR79.67]

[Page 567-570]
 
                   TITLE 40--PROTECTION OF ENVIRONMENT
 
         CHAPTER I--ENVIRONMENTAL PROTECTION AGENCY (CONTINUED)
 
PART 79--REGISTRATION OF FUELS AND FUEL ADDITIVES--Table of Contents
 
            Subpart F--Testing Requirements for Registration
 
Sec. 79.67  Glial fibrillary acidic protein assay.

    (a) Purpose. Chemical-induced injury of the nervous system, i.e., 
the brain, is associated with astrocytic hypertrophy at the site of 
damage (see O'Callaghan, 1988 in paragraph (e)(3) in this section). 
Assays of glial fibrillary acidic protein (GFAP), the major intermediate 
filament protein of astrocytes, can be used to document this response. 
To date, a diverse variety of chemical insults known to be injurious to 
the central nervous system have been shown to increase GFAP. Moreover, 
increases in GFAP can be seen at concentrations below those necessary to 
produce cytopathology as determined by routine Nissl stains (standard 
neuropathology). Thus it appears that assays of GFAP represent a 
sensitive approach for documenting the existence and location of 
chemical-induced injury of the central nervous system. Additional 
functional, histopathological, and biochemical tests are necessary to 
assess completely the neurotoxic potential of any chemical. This 
biochemical test is intended to be used in conjunction with 
neurohistopathological studies.

[[Page 568]]

    (b) Principle of the test method. (1) This guideline describes the 
conduct of a radioimmunoassay for measurement of the amount of GFAP in 
the brain of vehicle emission-exposed and unexposed control animals. It 
is based on modifications (O'Callaghan & Miller 1985 in paragraph 
(e)(5), O'Callaghan 1987 in paragraph (e)(1) of this section) of the 
dot-immunobinding procedure described by Jahn et al. (1984) in paragraph 
(e)(2) of this section. Briefly, brain tissue samples from study animals 
are assayed for total protein, diluted in dot-immunobinding buffer, and 
applied to nitrocellulose sheets. The spotted sheets are then fixed, 
blocked, washed and incubated in anti-GFAP antibody and 
[I125] Protein A. Bound protein A is then quantified by gamma 
spectrometry. In lieu of purified protein standards, standard curves are 
constructed from dilution of a single control sample. By comparing the 
immunoreactivity of individual samples (both control and exposed groups) 
with that of the sample used to generate the standard curve, the 
relative immunoreactivity of each sample is obtained. The 
immunoreactivity of the control groups is normalized to 100 percent and 
all data are expressed as a percentage of control. A variation on this 
radioimmunoassay procedure has been proposed (O'Callaghan 1991 in 
paragraph (e)(4) of this section) which uses a ``sandwich'' of GFAP, 
anti-GFAP, and a chromophore in a microtiter plate format enzyme-link 
immunosorbent assay (ELISA). The use of this variation shall be 
justified.
    (2) This assay may be done separately or in combination with the 
subchronic toxicity study, pursuant to the provisions of Sec. 79.62.
    (c) Test procedure--(1) Animal selection--(i) Species and strain. 
Test shall be performed on the species being used in concurrent testing 
for neurotoxic or other health effect endpoints. This will generally be 
a species of laboratory rat. The use of other rodent or non-rodent 
species shall be justified.
    (ii) Age. Based on other concurrent testing, young adult rats shall 
be used. Study rodents shall not be older than ten weeks at the start of 
exposures.
    (iii) Number of animals. A minimum of ten animals per group shall be 
used. The tissues from each animal shall be examined separately.
    (iv) Sex. Both sexes shall be used unless it is demonstrated that 
one sex is refractory to the effects.
    (2) Materials. The materials necessary to perform this study are 
[I125] Protein A (2-10 [mu]Ci/[mu]g), Anti-sera to GFAP, 
nitrocellulose paper (0.1 or 0.2 [mu]m pore size), sample application 
template (optional; e.g., ``Minifold II'', Schleicher & Schuell, Keene, 
NH), plastic sheet incubation trays.
    (3) Study conduct. (i) All data developed within this study shall be 
in accordance with good laboratory practice provisions under Sec. 79.60.
    (ii) Tissue Preparation. Animals are euthanized 24 hours after the 
last exposure and the brain is excised from the skull. On a cold 
dissecting platform, the following six regions are dissected freehand: 
cerebellum; cerebral cortex; hippocampus; striatum; thalamus/
hypothalamus; and the rest of the brain. Each region is then weighed and 
homogenized in 10 volumes of hot (70-90  deg.C) 1 percent (w/v) sodium 
dodecyl sulfate (SDS). Homogenization is best achieved through sonic 
disruption. A motor driven pestle inserted into a tissue grinding vessel 
is a suitable alternative. The homogenized samples can then be stored 
frozen at -70  deg.C for at least 4 years without loss of GFAP content.
    (iii) Total Protein Assay. Aliquots of the tissue samples are 
assayed for total protein using the method of Smith et al. (1985) in 
paragraph (e)(7) of this section. This assay may be purchased in kit 
form (e.g., Pierce Chemical Company, Rockford, IL).
    (iv) Sample Preparation. Dilute tissue samples in sample buffer (120 
mM KCl, 20 mM NaCl, 2 mM MgCl2), 5 mM Hepes, pH 7.4, 0.7 
percent Triton X-100) to a final concentration of 0.25 mg total protein 
per ml (5 [mu]g/20 [mu]l).
    (v) Preparation of Standard Curve. Dilute a single control sample in 
sample buffer to give at least five standards, between 1 and 10 [mu]g 
total protein per 20 [mu]l. The suggested values of total protein per 20 
[mu]l sample buffer are 1.25, 2.50, 3.25, 5.0, 6.25, 7.5, 8.75, and 10.0 
[mu]g.
    (vi) Preparation of Nitrocellulose Sheets. Nitrocellulose sheets of 
0.1 or

[[Page 569]]

0.2 micron pore size are rinsed by immersion in distilled water for 5 
minutes and then air dried.
    (vii) Sample Application. Samples can be spotted onto the 
nitrocellulose sheets free-hand or with the aid of a template. For free-
hand application, draw a grid of squares approximately 2 centimeters by 
2 centimeters (cm) on the nitrocellulose sheets using a soft pencil. 
Spot 5-10 [mu]l portions to the center of each square for a total sample 
volume of 20 [mu]l. For template aided sample application a washerless 
microliter capacity sample application manifold is used. Position the 
nitrocellulose sheet in the sample application device as recommended by 
the manufacturer and spot a 20 [mu]l sample in one application. Do not 
wet the nitrocellulose or any support elements prior to sample 
application. Do not apply vacuum during or after sample application. 
After spotting samples (using either method), let the sheets air dry. 
The sheets can be stored at room temperature for several days after 
sample application.
    (viii) Standard Incubation Conditions. These conditions have been 
described by Jahn et al. (1984) in paragraph (e)(2) of this section. All 
steps are carried out at room temperature on a flat shaking platform 
(one complete excursion every 2-3 seconds). For best results, do not use 
rocking or orbital shakers. Perform the following steps in enough 
solution to cover the nitrocellulose sheets to a depth of 1 cm.
    (A) Incubate 20 minutes in fixer (25 percent (v/v) isopropanol, 10 
percent (v/v) acetic acid).
    (B) Discard fixer, wash several times in deionized water to 
eliminate the fixer, and then incubate for 5 minutes in Tris-buffered 
saline (TBS): 200 mM NaCL, 60 mM Tris-HCl to pH 7.4.
    (C) Discard TBS and incubate 1 hour in blocking solution (0.5 
percent gelatin (w/v)) in TBS.
    (D) Discard blocking solution and incubate for 2 hours in antibody 
solution (anti-GFAP antiserum diluted to the desired dilution in 
blocking solution containing 0.1 percent Triton X-100). Serum anti-
bovine GFAP, which cross reacts with GFAP from rodents and humans, can 
be obtained commercially (e.g., Dako Corp.) and used at a dilution of 
1:500.
    (E) Discard antibody solution, and wash in 4 changes of TBS for 5 
minutes each time. Then wash in TBS for 10 minutes.
    (F) Discard TBS and incubate in blocking solution for 30 minutes.
    (G) Discard blocking solution and incubate for 1 hour in Protein A 
solution ([I\125\]-labeled Protein A diluted in blocking solution 
containing 0.1 percent Triton X-100, sufficient to produce 2000 counts 
per minute (cpm) per 10 [mu]l of Protein A solution).
    (H) Remove Protein A solution (it may be reused once). Wash in 0.1 
percent Triton X-100 in TBS (TBSTX) for 5 minutes, 4 times. Then wash in 
TBSTX for 2-3 hours for 4 additional times. An overnight wash in a 
larger volume can be used to replace the last 4 washes.
    (I) Hang sheets to air-dry. Cut out squares or spots and count 
radioactivity in a gamma counter.
    (ix) Expression of data. Compare radioactivity counts for samples 
obtained from control and treated animals with counts obtained from the 
standard curve. By comparing the immunoreactivity (counts) of each 
sample with that of the standard curve, the relative amount of GFAP in 
each sample can be determined and expressed as a percent of control.
    (d) Data Reporting and Evaluation--(1) Test Report. In addition to 
information meeting the requirements stated under 40 CFR 79.60, the 
following specific information shall be reported:
    (i) Body weight and brain region weights at time of sacrifice for 
each subject tested;
    (ii) Indication of whether each subject survived to sacrifice or 
time of death;
    (iii) Data from control animals and blank samples; and
    (iv) Statistical evaluation of results;
    (2) Evaluation of Results. (i) Results shall be evaluated in terms 
of the extent of change in the amount of GFAP as a function of treatment 
and dose. GFAP assays (of any brain region) from a minimum of 6 samples 
typically will result in a standard error of the mean of 5 
percent. In this case, a chemically-induced increase in GFAP

[[Page 570]]

of 115 percent of control is likely to be statistically significant.
    (ii) The results of this assay shall be compared to and evaluated 
with any relevant behavioral and histopathological data.
    (e) References. For additional background information on this test 
guideline the following references should be consulted.
    (1) Brock, T.O and O'Callaghan, J.P. 1987. Quantitative changes in 
the synaptic vesicle proteins, synapsin I and p38 and the astrocyte 
specific protein, glial fibrillary acidic protein, are associated with 
chemical-induced injury to the rat central nervous system, J. Neurosci. 
7:931-942.
    (2) Jahn, R., Schiebler, W. Greengard, P. 1984. A quantitative dot-
immunobinding assay for protein using nitrocellulose membrane filters. 
Proc. Natl. Acad. Sci. U.S.A. 81:1684-1687.
    (3) O'Callaghan, J.P. 1988. Neurotypic and gliotypic protein as 
biochemical markers of neurotoxicity. Neurotoxicol. Teratol. 10:445-452.
    (4) O'Callaghan, J.P. 1991. Quantification of glial fibrillary 
acidic protein: comparison of slot-immunobinding assays with a novel 
sandwich ELISA. Neurotoxicol. Teratol. 13:275-281.
    (5) O'Callaghan, J.P. and Miller, D.B. 1985. Cerebellar hypoplasia 
in the Gunn rat is associated with quantitative changes in neurotypic 
and gliotypic proteins. J. Pharmacol. Exp. Ther. 234:522-532.
    (6) Sette, W.F. ``Pesticide Assessment Guidelines, Subdivision `F', 
Hazard Evaluation: Human and Domestic Animals, Addendum 10, 
Neurotoxicity, Series 81, 82, and 83'' US-EPA, Office of Pesticide 
Programs, EPA-540/09-91-123, March 1991.
    (7) Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., 
Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, 
B.J., Klenk, D.C. 1985. Measurement of protein using bicinchoninic acid. 
Annal. Biochem. 150:76-85.